Can ADH be cancer? ADH is a benign breast condition linked to a moderate increase in breast cancer risk. If you have a core needle biopsy that discovers atypical cells, your doctor likely will go on to remove more of the tissue in that area. Since ADH is not a true cancer, though, there can be some variation in how doctors approach them.
How often does atypical ductal hyperplasia turn into cancer? Specifically, five years after the diagnosis of atypical hyperplasia, 7% of women will develop breast cancer. Ten years after the diagnosis, 13% of these women will develop cancer. Twenty-five years after the diagnosis, 30% of these women will develop breast cancer.
How common is ADH breast? Atypical ductal hyperplasia (ADH) is a relatively common lesion reported to be found in about 5% to 20% of breast biopsies. Although not carcinoma, it is classified as a high-risk precursor lesion due to its association with and potential to progress to ductal carcinoma in situ (DCIS) as well as invasive carcinoma.
How is ADH breast treated? Atypical hyperplasia is generally treated with surgery to remove the abnormal cells and to make sure no in situ or invasive cancer also is present in the area. Doctors often recommend more-intensive screening for breast cancer and medications to reduce your breast cancer risk.